Arvinas 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .Commission File Number: 001-38672__________________________________________ ARVINAS, INC. (Exact name of registrant as specified in its Charter)__________________________________________ Registrant’s telephone number, including area code:(203) 535-1456 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit such files). YesNoIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer Accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐NoAs of May7, 2026, the registrant had 64,521,198 shares of common stock, $0.001 par value per share, outstanding. Table of Contents Table of Contents PagePART I.FINANCIAL INFORMATION2 Item 1.Financial Statements (Unaudited)2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income3Condensed Consolidated Statements of Changes in Stockholders’ Equity4Condensed Consolidated Statements of Cash Flows5Notes to Condensed Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk41Item 4.Controls and Procedures41 PART II.OTHER INFORMATION42 Item 1.Legal Proceedings42Item 1A.Risk Factors42Item 2.Unregistered Sales of Equity Securities and Use of Proceeds44Item 5.Other Information44Item 6.Exhibits46 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks anduncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q,including statements regarding our strategy, future operations, future financial position, future revenues, projected costs,prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,”“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “goals,” “will,” “would,” “could,”“should,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statementsabout: •the initiation, timing, progress and results of our current and/or future clinical trials of ARV-102, ARV-806, ARV-393and ARV-027, including statements regarding the period during which the results of the clinical trials will becomeavailable or the forum in which we will present such results;•the initiation, timing, progress and results of our current preclinical studies and any future preclinical studies orclinical trials of our other programs, including ARV-6723 and our pan-KRAS degrader, including statementsregarding the period during which the results of preclinical studies or clinical trials will become available or theforum in which we will present such results;•our belief, based on data from our preclinical studies and clinical trials, that PROTAC protein degraders may havedistinct advantages over traditional small molecule inhibitors, antibodies and gene-based medicines;•our belief that PROTAC degraders offer distinct advantages that enable perturbation of protein targets traditionallyconsidered undruggable by conventional therapeutics;•the timing of, and our ability to obtain, marketing approval of our product candidates and the ability of our productcandidates to meet existing or future regulatory st